scholarly journals UTILIZATION TRENDS OF NEWLY APPROVED GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S581-S581
Author(s):  
Chintan Dave ◽  
Dae Kim ◽  
Elisabetta Patorno
Keyword(s):  
Type 2 Diabetes ◽  
Standard Deviation ◽  
Fee For Service ◽  
Glucose Lowering ◽  
Medicare Population ◽  
Prior Use ◽  
Lowering Drug ◽  
Service Data

Abstract Using Medicare fee-for-service data from 2013-2015, we identified 3.2 million patients per year (mean [SD] age, 74.7 years [standard deviation, 7.2]) who were treated with glucose-lowering drugs for type 2 diabetes. Between 2013 and 2015, the proportion of patients treated with sulfonylureas declined from 27.4% to 25.1%; those using DPP4is (11.5% to 12.0%) and GLP1-RAs (1.8% to 2.4%) remained unchanged; those using SGLT2is increased from 0.2% to 1.9%. In the subgroup of patients initiating a glucose-lowering drug without prior use of the same class agent, the proportion of patients starting sulfonylureas (18.7% to 17.2% of initiators), DPP4is (16.0% to 15.0% of initiators), and GLP1-RAs (3.4% to 4.2% of initiators) changed little between 2013 and 2015, while those starting SGLT2is increased from 0.7% to 6.5% of initiators. In the Medicare population, we observed a persistently high use of sulfonylureas and a rapid uptake of SGLT2is among the newer classes.

scholarly journals Monitoring Utilization Trends of Glucose-Lowering Drugs for Type 2 Diabetes in Older Adults by Frailty Status

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 210-210
Author(s):  
Dae Kim ◽  
Alexander Kutz ◽  
Elisabetta Patorno ◽  
Chandrasekar Gopalakrishnan
Keyword(s):  
Type 2 Diabetes ◽  
Older Adults ◽  
Fee For Service ◽  
Glucose Lowering ◽  
Frailty Status ◽  
Frail Patients ◽  
Lowering Drug ◽  
Service Data ◽  
Over Time

Abstract Using Medicare fee-for-service data from 2013-17, we identified a cohort of patients with type 2 diabetes (T2D) who initiated a glucose-lowering drug (mean [SD] age, 74.8 (6.9) years). Amongst frail patients (CFI≥0.20), metformin use remained stable from 29.1% to 29.4%, whereas sulfonylureas (25.8% to 22.1%) and insulin (21.2% to 19.0%) use declined. Amongst non-frail patients (CFI <0.20), metformin (35.3% to 33.1%) and sulfonylurea (26.2% to 22.2%) use decreased whereas insulin (11.7% to 10.6%) use remained stable. DPP-4i and glitazones use remained stable whereas the use of newer agents such as SGLT-2i and GLP-1 RA increased steadily over the study period in both frail and non-frail patients, though their use remains low ( <8%). In conclusion, sulfonylureas and insulin accounted for about one-third of initiated glucose-lowering medications and were more frequently used by frail patients, though their use declined steadily over time with the availability of newer agents.

Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA

Diabetes Care ◽  
2021 ◽  
pp. dc202926
Author(s):  
HoJin Shin ◽  
Sebastian Schneeweiss ◽  
Robert J. Glynn ◽  
Elisabetta Patorno
Keyword(s):  
Type 2 Diabetes ◽  
Drug Use ◽  
First Line ◽  
Glucose Lowering ◽  
Lowering Drug

977-P: Trends in First-Line Glucose-Lowering Drug Use in Adults with Type 2 Diabetes in Light of Emerging Evidence for SGLT2i and GLP-1RA

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 977-P
Author(s):  
HOJIN SHIN ◽  
SEBASTIAN SCHNEEWEISS ◽  
ROBERT GLYNN ◽  
ELISABETTA PATORNO
Keyword(s):  
Type 2 Diabetes ◽  
Drug Use ◽  
First Line ◽  
Glucose Lowering ◽  
Lowering Drug

343-OR: Trends in A1C and Lipid Testing, Antilipid Therapy, and Target Attainment following First-Time Glucose-Lowering Drug Treatment in Type 2 Diabetes, Denmark, 2000-2017

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 343-OR
Author(s):  
JAKOB S. KNUDSEN ◽  
DANIEL R. WITTE ◽  
ADAM HULMAN ◽  
PERNILLE F. RØNN ◽  
TORSTEN LAURITZEN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Drug Treatment ◽  
Target Attainment ◽  
Glucose Lowering ◽  
Lipid Testing ◽  
Lowering Drug ◽  
First Time

scholarly journals The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes

2015 ◽  
Vol 150 (2) ◽  
pp. 427-437 ◽  
Author(s):  
Pauline A. J. Vissers ◽  
Chris R. Cardwell ◽  
Lonneke V. van de Poll-Franse ◽  
Ian S. Young ◽  
Frans Pouwer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Drug Use ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Glucose Lowering ◽  
Lowering Drug

scholarly journals Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A467-A467
Author(s):  
Muhammad Saleem ◽  
Nanik Ram ◽  
Sajjad Ali Khan ◽  
Zafar Aleem Suchal ◽  
Muhammad Mustansir Mehdi Khan
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Standard Deviation ◽  
P Value ◽  
Oral Glucose ◽  
Glucose Lowering

Abstract Background: SGLT-2 inhibitors are a group of oral medications that work independently of insulin working as anti-diabetics by enhancing the excretion of glucose. The purpose of our study was to assess the improvement in terms of HbA1c, weight, blood pressure and BMI and the hepatics and renal effect in terms of SGPT and Creatinine in patients already on three oral glucose lowering agents when SGLT-2 inhibitor was added to their medications. Methods: This retrospective, real world, single center study included 99 patients (mean age [Standard Deviation]: 53.8 [9.63] years) with poorly control type 2 diabetes. Data was recorded at three times, before the addition of SGLT-2 inhibitor and then at 3 and 6 month follow up after the drug had been added in patient’s medications. Physical parameters namely weight, BMI and blood pressure were recorded in the clinic while HbA1c, SGPT and Creatinine were checked by laboratory. Results: Improvement was seen in all parameters at both 3 and 6 month follow up interval. The reduction in HbA1c was statistically significant (P-value < 0.001) with (Mean Reduction [Standard Deviation)) 0.81[1.02] % at 3 months and 1.07[1.11] % at 6 months. Weight was also significantly reduced (P-value < 0.001) with (MR [SD]) 1.83[2.32] kg at 3 and 4.02[6.04] kg at 6 months. Statistically significant reduction (P-value < 0.001) in BMI was also seen with 0.69[0.95] kgm-2 at 3 months and 2.13[3.41] kgm-2 at 6 months of follow up. The systolic blood pressure showed significant reduction (P-value < 0.05) of 5.9[15.76] mmHg at 3 months and 6.37[18.33] mmHg at 6 months. The creatinine and SGPT values of the patient showed minimal variation over the course of these 6 months of follow up. Conclusion: Our study showed that SGPT-2 can be reliably used in patients in which diabetes is not being controlled by other glucose lowering agents and is safe for use in patients in which hepatic and renal function needs to be preserved. Keywords: SGLT-2 inhibitors, Type 2 Diabetes Mellitus, Pakistan

Sign in / Sign up

Export Citation Format

Share Document